NCT05914610尚未招募3 期
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Her-2 Negative Unresectable Locally Advanced Gastric Cancer: a National Multicenter Randomized Controlled Study
Fujian Medical University0 个研究点目标入组 100 人开始时间: 2023年9月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
- 主要终点
- Surgical conversion rate
研究概览
简要总结
To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18-75 years of age;
- •Pathological (including histological or cytological) confirmation of gastric adenocarcinoma;
- •Before surgery, CT/MRI, PET-CT, if necessary, laparoscopic exploration to determine the clinical stage of T4bN0M0 and TanyN2-3M0, and determined by researchers that the local advanced patients can not be resectable;
- •At least one measurable detected by CT examination in accordance with the RECIST1.1
- •ECOG#Eastern Cooperative Oncology Group#PS#Performance Status#:0-1 scores;
- •The expected survival time is more than 3 months
- •The main organ function is normal, which should meet the following criteria:
- •#1#blood routine examination standards should be met#no blood transfusion within 14 days#
- •a.HB≥ 100g/L b. WBC≥3×109/L c. ANC≥1.5×109/L d. PLT≥100×109/L #2#biochemical examination shall comply with the following criteria#
- •BIL#1.5 normal upper limit ULN
- •ALT and AST#2.5 ULN
- •Cr≤1 ULN#CCR#creatinine clearance rate##60ml/min(Cockcroft Gault formula)
- •Women of childbearing age must have a pregnancy test in 7 days before entering the group (in serum), and the results were negative, and willing to use appropriate contraception during the study period and the last 8 weeks after giving drug test; men should have the surgical sterilization, or adopt the appropriate contraceptive methods during the test and the last 8 weeks after giving drug test#
- •No other clinical studies were conducted before and during the treatment
- •Participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up
排除标准
- •Imaging or intraoperative exploration found patients with peritoneum, liver, lung and other distant metastases
- •Patients with allergies or suspected allergies to study drugs or similar drugs
- •Confirmed HER-2 positive patients
- •Other malignancies in the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix
- •Live vaccine was administered within 4 weeks prior to enrolling or possibly during the study period
- •Had an active autoimmune disease or a history of autoimmune disease within 4 weeks prior to enrollment
- •Past recipients of allogeneic bone marrow transplants or organ transplants
- •Patient has any current disease or condition that affects drug absorption, or the patient is unable to take the drug orally
- •The blood pressure of patients with hypertension cannot be reduced to the normal range by the one antihypertensive drugs (systolic pressure ≥150 mmHg, diastolic pressure ≥100 mmHg) or hard to controled by two or more antihypertensive drugs
- •Patients are positive of urine protein (urine protein detection 2+ or above, or 24 hours urine protein quantitative >1.0g)
- •The patient currently has gastrointestinal diseases such as active gastric and duodenal ulcers, ulcerative colitis, or active bleeding from unresectosed tumors, or other conditions determined by researchers that may cause gastrointestinal bleeding or perforation
- •Patients with significant evidence or history of bleeding tendency within 3 months prior to enrollment (bleeding within 3 months >30 mL, hematemesis, black stool, blood in stool), hemoptysis (within 4 weeks >5 mL fresh blood) or a thromboembolic event (including stroke and/or transient ischemic attack) within 12 months
- •Cardiovascular disease of significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure more than class II ; Ventricular arrhythmias requiring medical treatment; An electrocardiogram (ECG) showed a QT c interval ≥480 milliseconds
- •Active or uncontrolled severe infection (≥CTCAE grade 2 infection)
- •A history of human immunodeficiency virus (HIV) infection or clinically significant liver disease, including viral hepatitis [active HBV infection must be ruled out as a known carrier of hepatitis B virus (HBV), i.e. positive HBV DNA (>1×104 copies /mL or >2000 IU/ml); known hepatitis C virus infection (HCV) and HCV RNA positive (>1×103 copies /mL), or other hepatitis, cirrhosis]
- •The researchers consider those who were not suitable for inclusion
研究组 & 干预措施
Envolimab + fruquinitinib +SOX regimen
Experimental
干预措施: Oxaliplatin (Drug)
Envolimab + fruquinitinib +SOX regimen
Experimental
干预措施: Envolimab (Drug)
Envolimab + fruquinitinib +SOX regimen
Experimental
干预措施: Fruquintinib (Drug)
Envolimab + fruquinitinib +SOX regimen
Experimental
干预措施: Tegafur (Drug)
SOX regimen
Active Comparator
干预措施: Oxaliplatin (Drug)
SOX regimen
Active Comparator
干预措施: Tegafur (Drug)
结局指标
主要结局
Surgical conversion rate
时间窗: 2-3 months
Defined as the proportion of patients who have undergone surgical resection after multidisciplinary assessment after completing 4-6 cycles of conversion therapy
次要结局
- Pathological complete response (pCR)(4 months)
- Median survival time(3 years)
- Objective response rate (ORR)(4 months)
- R0 resection rate(2-3 month)
- Adverse event (AEs)(2 years)
- Median disease free survival (DFS) time(3 years)
- 3-year DFS rate(3 years)
- 1-year DFS rate(1 year)
- Major pathological response rate (MPR)(4 months)
- Quality of life (QOL)(2 years)
研究者
Chang-Ming Huang, Prof.
Clinical Professor
Fujian Medical University
相似试验
尚未招募
2 期
Combined Treatment of Treated Bile Duct CancerBile Duct CancerNCT05911425Zhejiang Cancer Hospital30
招募中
不适用
Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI TherapyRenal Cell Carcinoma, Clear Cell, SomaticNCT06317298Peking University First Hospital36
尚未招募
2 期
Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma PatientsEfficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma PatientsNCT05722977Peking Union Medical College Hospital45
尚未招募
2 期
Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced CancerGastric CancerNCT06094868Second Affiliated Hospital of Nanchang University45
终止
2 期
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal CancerColorectal NeoplasmsNCT00609622Pfizer191